SVRA 3.60 Savara Inc.
| Range: | 3.115-5.7 | Vol Avg: | 1117400 | Last Div: | 0 | Changes: | 0.17 |
| Beta: | 0.95 | Cap: | 0.62B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Apr 28 2017 | Empoloyees: | 37 | ||
| CUSIP: | 805111101 | CIK: | 0001160308 | ISIN: | US8051111016 | Country: | US |
| CEO: | Mr. Matthew Pauls J.D., M.B.A. | Website: | https://www.savarapharma.com | ||||
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Stock Details
SVRA 9
Savara price target lowered to $9 from $10 at JMP Securities
Jonathan Wolleben·Tue Aug 13 2024
JMP Securities
SVRA 10
Savara price target raised to $10 from $8 at Guggenheim
Vamil Divan·Thu Jun 27 2024
Guggenheim
SVRA 10
Savara price target raised to $10 from $6 at H.C. Wainwright
Andrew Fein·Thu Jun 27 2024
H.C. Wainwright
SVRA 10
Savara (SVRA) PT Raised to $10 at JMP Securities
Jonathan Wolleben·Thu Jun 27 2024
JMP Securities
SVRA 11
Savara (SVRA) PT Raised to $11 at Oppenheimer
Francois Brisebois·Tue May 21 2024
Oppenheimer
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow